Online Program

Medication Assisted Treatment Capacity and Leveraging Data Systems to Identify and Connect People to Treatment

Tuesday, November 3, 2015 : 11:10 a.m. - 11:30 a.m.

Christopher Jones, PharmD, MPH, Food and Drug Administration, Office of the Commissioner, Silver Spring, MD

Morbidity and mortality related to opioid use disorders is a significant public health problem in the United States. In 2013, over 16,000 drug overdose deaths involved prescription opioid analgesics and over 8,000 deaths involved heroin. In fact, overdose deaths involving heroin have more than doubled since 2010. In addition, research has shown that the majority of current heroin users used prescription opioids prior to initiating heroin use. Thus. treating opioid use disorders through medication assisted treatment is a key strategy for reducing both prescription opioid and heroin-related morbidity and mortality. However, there is a significant gap in treatment capacity in the United States. Even in areas where capacity exists, patients in need of treatment are often not able to connect with the proper treatment. Data sources such as prescription drug monitoring programs, insurer and pharmacy benefit manager claims review systems, and integrated electronic health records can be used to help identify individuals in need of treatment. This session will discuss the current treatment gap for medication assisted treatment in the United States, describe how prescription drug monitoring program data and other data sources can be used to identify and intervene early so people with opioid use disorders can receive treatment, and discuss various policies related to medication assisted treatment capacity and access.

Learning Areas:

Provision of health care to the public
Systems thinking models (conceptual and theoretical models), applications related to public health

Learning Objectives:
Discuss the treatment gap for medication-assisted treatment capacity and need in the United States and steps that can be taken to address it. Describe how data from prescription drug monitoring programs and medical claims data sources can be used to identify patients in need of treatment for opioid use disorders.

Keyword(s): Treatment System, Accessibility

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: Dr. Jones was principal investigator on a study examining medication-assisted treatment (MAT) capacity at the national and state levels. He is science officer on a collaborative project with the FDA, CDC, and the Prescription Drug Monitoring Program (PDMP) Center of Excellence at Brandeis University developing a Prescription Behavior Surveillance System (PBSS). He is experienced PDMP and claims data research identifying inappropriate substance use and appropriate candidates for SUD treatment, or MAT for opioid use disorders.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.